DCTH Delcath Systems Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: DCTH

Price (delayed)

$17.14

Market cap

$594.74M

P/E Ratio

1,714

Dividend/share

N/A

EPS

$0.01

Enterprise value

$549.68M

?
Relative Growth: Rel. Growth: 59
Relative Strength: Rel. Strength: 92
Relative Valuation: Rel. Valuation: 11
Relative Profitability: Rel. Profitability: 41

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The company's proprietary products, HEPZATO KIT™ (HEPZATO (melphalan) for Injection/Hepatic Delivery System) ...

Highlights
Delcath Systems's gross profit has increased by 38% YoY and by 7% from the previous quarter
The company's revenue rose by 36% YoY and by 6% QoQ
Delcath Systems's debt has surged by 172% QoQ and by 148% YoY
Delcath Systems's EPS has plunged by 88% YoY and by 50% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://delcath.com
Peers: ICUI ANGO PODD RVP

Key stats

What are the main financial stats of DCTH

DCTH stock price

How has the Delcath Systems stock price performed over time
Intraday
2.33%
1 week
2.45%
1 month
33.8%
1 year
64.65%
YTD
69.7%
QTD
36.14%

Financial performance

How have Delcath Systems's revenue and profit performed over time
Revenue
$95.42M
Gross profit
$83.06M
Operating income
-$1.9M
Net income
$532,000
Gross margin
87.1%
Net margin
0.6%
The operating income has dropped by 138% year-on-year and by 10% since the previous quarter
DCTH's operating margin has dropped by 129% year-on-year and by 5% since the previous quarter
Delcath Systems's net margin has shrunk by 81% YoY
The net income has plunged by 76% YoY and by 5% from the previous quarter

Price vs fundamentals

How does DCTH's price correlate with its fundamentals

Growth

What is Delcath Systems's growth rate over time

Valuation

What is Delcath Systems stock price valuation
P/E
1,714
P/B
4.88
P/S
6.45
EV/EBIT
214.8
EV/EBITDA
179.58
EV/Sales
5.76
Delcath Systems's EPS has plunged by 88% YoY and by 50% from the previous quarter
DCTH's P/B is 53% higher than its last 4 quarters average of 3.2
Delcath Systems's equity has increased by 15% YoY and by 7% from the previous quarter
The price to sales (P/S) is 59% less than the 5-year quarterly average of 15.7 but 47% more than the last 4 quarters average of 4.4
The company's revenue rose by 36% YoY and by 6% QoQ

Efficiency

How efficient is Delcath Systems business performance
The ROA has shrunk by 86% YoY and by 20% QoQ
The ROE has dropped by 85% year-on-year
The company's return on invested capital fell by 40% YoY and by 6% QoQ
Delcath Systems's ROS has decreased by 29% YoY and by 7% from the previous quarter

Dividends

What is DCTH's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for DCTH.

Financial health

How did Delcath Systems financials performed over time
DCTH's total liabilities is up by 33% year-on-year and by 31% since the previous quarter
The total assets has grown by 17% year-on-year and by 10% since the previous quarter
Delcath Systems's debt is 98% lower than its equity
Delcath Systems's debt has surged by 172% QoQ and by 148% YoY
DCTH's debt to equity has soared by 100% QoQ and by 100% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.